CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Vertex Pharmaceuticals Incorporated - VRTX CFD

    397.32
    0.23%
    0.34
    Low: 396.5
    High: 401.87
    Market Trading Hours* (UTC) Opens on Tuesday at 13:30

    Mon - Fri: 13:30 - 20:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.34
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Vertex Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 396.41
    Open* 399.92
    1-Year Change* 20.06%
    Day's Range* 396.5 - 401.87
    52 wk Range 283.60-439.77
    Average Volume (10 days) 1.33M
    Average Volume (3 months) 29.24M
    Market Cap 111.57B
    P/E Ratio 32.50
    Shares Outstanding 257.68M
    Revenue 9.65B
    EPS 13.32
    Dividend (Yield %) N/A
    Beta 0.36
    Next Earnings Date Feb 5, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 15, 2024 397.32 -2.39 -0.60% 399.71 402.09 396.50
    Apr 12, 2024 396.41 -0.55 -0.14% 396.96 399.96 393.34
    Apr 11, 2024 399.74 -3.18 -0.79% 402.92 403.52 398.35
    Apr 10, 2024 397.31 -1.02 -0.26% 398.33 399.63 394.48
    Apr 9, 2024 404.13 -0.69 -0.17% 404.82 405.73 398.82
    Apr 8, 2024 403.77 2.57 0.64% 401.20 404.45 397.17
    Apr 5, 2024 406.39 4.07 1.01% 402.32 409.75 399.95
    Apr 4, 2024 403.49 -6.55 -1.60% 410.04 411.75 402.58
    Apr 3, 2024 408.69 0.50 0.12% 408.19 414.73 404.45
    Apr 2, 2024 409.31 -9.82 -2.34% 419.13 420.15 406.49
    Apr 1, 2024 420.13 0.35 0.08% 419.78 421.13 413.61
    Mar 28, 2024 417.95 1.29 0.31% 416.66 420.33 411.89
    Mar 27, 2024 417.17 -1.17 -0.28% 418.34 419.69 412.13
    Mar 26, 2024 418.31 2.42 0.58% 415.89 419.26 414.42
    Mar 25, 2024 415.77 1.98 0.48% 413.79 418.08 413.79
    Mar 22, 2024 415.60 -0.72 -0.17% 416.32 417.25 411.66
    Mar 21, 2024 415.68 0.83 0.20% 414.85 418.98 413.20
    Mar 20, 2024 411.74 0.20 0.05% 411.54 414.41 408.13
    Mar 19, 2024 414.76 2.35 0.57% 412.41 415.48 410.23
    Mar 18, 2024 410.80 1.49 0.36% 409.31 415.33 408.23

    Vertex Pharmaceuticals Incorporated Events

    Time (UTC) Country Event
    Monday, May 6, 2024

    Time (UTC)

    20:00

    Country

    US

    Event

    Q1 2024 Vertex Pharmaceuticals Inc Earnings Release
    Q1 2024 Vertex Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -

    Time (UTC)

    20:30

    Country

    US

    Event

    Q1 2024 Vertex Pharmaceuticals Inc Earnings Call
    Q1 2024 Vertex Pharmaceuticals Inc Earnings Call

    Forecast

    -

    Previous

    -
    Wednesday, May 15, 2024

    Time (UTC)

    13:00

    Country

    US

    Event

    Vertex Pharmaceuticals Inc Annual Shareholders Meeting
    Vertex Pharmaceuticals Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Thursday, May 16, 2024

    Time (UTC)

    13:00

    Country

    US

    Event

    Vertex Pharmaceuticals Inc Annual Shareholders Meeting
    Vertex Pharmaceuticals Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Tuesday, July 30, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q2 2024 Vertex Pharmaceuticals Inc Earnings Release
    Q2 2024 Vertex Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 8930.7 7574.4 6205.68 4162.82 3047.6
    Revenue 8930.7 7574.4 6205.68 4162.82 3047.6
    Cost of Revenue, Total 1080.3 904.2 736.3 547.758 409.539
    Gross Profit 7850.4 6670.2 5469.38 3615.06 2638.06
    Total Operating Expense 4623.3 4792.3 3349.39 2965.25 2412.45
    Selling/General/Admin. Expenses, Total 944.7 840.1 770.456 658.498 557.616
    Research & Development 2642.8 3051.1 1829.54 1754.54 1416.48
    Unusual Expense (Income) 13 0 0 28.816
    Other Operating Expenses, Total -57.5 -3.1 13.1 4.459
    Operating Income 4307.4 2782.1 2856.29 1197.57 635.15
    Interest Income (Expense), Net Non-Operating -59.3 -39.5 100.255 10.014 -33.496
    Other, Net -15.7 -12.2 160.253 187.339 -1.413
    Net Income Before Taxes 4232.4 2730.4 3116.8 1394.92 600.241
    Net Income After Taxes 3322 2342.1 2711.65 1176.81 527.103
    Minority Interest 0 0 9.793
    Net Income Before Extra. Items 3322 2342.1 2711.65 1176.81 536.896
    Total Extraordinary Items 1560
    Net Income 3322 2342.1 2711.65 1176.81 2096.9
    Income Available to Common Excl. Extra. Items 3322 2342.1 2711.65 1176.81 536.395
    Income Available to Common Incl. Extra. Items 3322 2342.1 2711.65 1176.81 2096.4
    Diluted Net Income 3322 2342.1 2711.65 1176.81 2096.4
    Diluted Weighted Average Shares 259.1 259.9 263.396 260.673 259.185
    Diluted EPS Excluding Extraordinary Items 12.8213 9.01154 10.2949 4.51451 2.06954
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS 12.8607 9.01154 10.2949 4.51451 2.16718
    Total Adjustments to Net Income 0 -0.501
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 2493.2 2374.8 2302.7 2334.3 2196.2
    Revenue 2493.2 2374.8 2302.7 2334.3 2196.2
    Cost of Revenue, Total 308.6 266.9 283.3 289.4 261.8
    Gross Profit 2184.6 2107.9 2019.4 2044.9 1934.4
    Total Operating Expense 1466.8 1595.8 1269.2 1207.6 1089.9
    Selling/General/Admin. Expenses, Total 262.6 241.1 267.4 246.8 215.3
    Research & Development 896.2 1089.7 716.7 674 649
    Unusual Expense (Income) 0 0 13
    Operating Income 1026.4 779 1033.5 1126.7 1106.3
    Interest Income (Expense), Net Non-Operating 142.7 117.6 68.4 49.2 -88
    Other, Net -7.6 -5.1 -25.1 0.5 6.1
    Net Income Before Taxes 1161.5 891.5 1076.8 1176.4 1024.4
    Net Income After Taxes 915.7 699.8 818.9 930.5 810.5
    Net Income Before Extra. Items 915.7 699.8 818.9 930.5 810.5
    Net Income 915.7 699.8 818.9 930.5 810.5
    Income Available to Common Excl. Extra. Items 915.7 699.8 818.9 930.5 810.5
    Income Available to Common Incl. Extra. Items 915.7 699.8 818.9 930.5 810.5
    Diluted Net Income 915.7 699.8 818.9 930.5 810.5
    Diluted Weighted Average Shares 260.4 260.3 260.3 259.5 258.7
    Diluted EPS Excluding Extraordinary Items 3.51651 2.68844 3.14599 3.58574 3.13297
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS 3.51651 2.68844 3.14599 3.58574 3.17273
    Other Operating Expenses, Total -0.6 -1.9 1.8 -2.6 -49.2
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 13234.8 9560.6 8133.38 4822.83 3843.11
    Cash and Short Term Investments 10778.5 7524.9 6658.9 3808.29 3168.24
    Cash & Equivalents 10504 6795 5988.19 3109.32 2650.13
    Short Term Investments 274.5 729.9 670.71 698.972 518.108
    Total Receivables, Net 1442.2 1136.8 885.352 633.518 414.87
    Accounts Receivable - Trade, Net 1442.2 1136.8 885.352 633.518 409.688
    Total Inventory 460.6 353.1 280.777 167.502 124.36
    Prepaid Expenses 553.5 545.8 308.353 203.79 55.022
    Other Current Assets, Total 9.725 80.615
    Total Assets 18150.9 13432.5 11751.8 8318.46 6245.9
    Property/Plant/Equipment, Total - Net 1455.8 1424.4 1284.1 833.282 812.005
    Property/Plant/Equipment, Total - Gross 2483.1 2320.4 2074.68 1525.82 1263.45
    Accumulated Depreciation, Total -1027.3 -896 -790.58 -692.54 -451.443
    Goodwill, Net 1088 1002.2 1002.16 1002.16 50.384
    Intangibles, Net 603.6 400 400 400 0
    Long Term Investments 98.6 85.8 20.8
    Note Receivable - Long Term
    Other Long Term Assets, Total 1670.1 959.5 911.373 1260.2 1540.4
    Total Current Liabilities 2742.1 2142 1877.53 1334.83 1120.29
    Accounts Payable 303.9 195 155.139 87.61 110.987
    Accrued Expenses 2052 1500.6 1311.32 1056.12 604.495
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 40.8 46.9 42.434 30.293 9.817
    Other Current Liabilities, Total 345.4 399.5 368.641 160.801 394.993
    Total Liabilities 4238.2 3332.5 3064.99 2233.22 1810.69
    Total Long Term Debt 430.8 509.8 539.042 538.576 581.55
    Long Term Debt
    Capital Lease Obligations 430.8 509.8 539.042 538.576 581.55
    Deferred Income Tax 0
    Minority Interest 0
    Other Liabilities, Total 1065.3 680.7 648.418 359.818 108.853
    Total Equity 13912.7 10100 8686.82 6085.24 4435.2
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 2.6 2.5 2.599 2.589 2.546
    Additional Paid-In Capital 7386.5 6880.8 7894.03 7937.61 7421.48
    Retained Earnings (Accumulated Deficit) 6522.8 3200.8 858.669 -1852.98 -2989.48
    Unrealized Gain (Loss) -0.1 -0.5 0.334 0.503 -0.536
    Other Equity, Total 0.9 16.4 -68.814 -2.476 1.195
    Total Liabilities & Shareholders’ Equity 18150.9 13432.5 11751.8 8318.46 6245.9
    Total Common Shares Outstanding 257.012 254.479 259.89 258.993 255.172
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 14695.8 13872.9 12965.7 13234.8 12271
    Cash and Short Term Investments 11928.2 11236.3 10414.1 10778.5 9770.7
    Cash & Equivalents 11110.2 10151.1 9289.9 10504 9171.5
    Short Term Investments 818 1085.2 1124.2 274.5 599.2
    Total Receivables, Net 1538.7 1556.2 1547.8 1442.2 1385.2
    Accounts Receivable - Trade, Net 1538.7 1556.2 1547.8 1442.2 1385.2
    Total Inventory 688.7 603.5 535.1 460.6 388.2
    Prepaid Expenses 502.4 470.1 449.2 553.5 535.3
    Other Current Assets, Total 37.8 6.8 19.5 191.6
    Total Assets 21726.2 20349.2 18974.2 18150.9 16706.4
    Property/Plant/Equipment, Total - Net 1434.5 1446.7 1448 1455.8 1461.4
    Goodwill, Net 1088 1088 1088 1088 1075.2
    Intangibles, Net 603.6 603.6 603.6 603.6 603.6
    Long Term Investments 1798.6 1455.9 1180.1 98.6 98.6
    Other Long Term Assets, Total 2105.7 1882.1 1688.8 1670.1 1196.6
    Total Current Liabilities 3599.4 3352.1 3026.2 2742.1 2609.3
    Accounts Payable 375.9 363 323.2 303.9 126.9
    Accrued Expenses 2907.3 2598.1 2326 2126.7 2264.4
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 316.2 391 377 311.5 218
    Total Liabilities 5213.4 4879 4541.9 4238.2 3676.8
    Total Long Term Debt 390.3 404.1 417.6 430.8 442.3
    Capital Lease Obligations 390.3 404.1 417.6 430.8 442.3
    Other Liabilities, Total 1223.7 1122.8 1098.1 1065.3 625.2
    Total Equity 16512.8 15470.2 14432.3 13912.7 13029.6
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 2.6 2.6 2.6 2.6 2.6
    Additional Paid-In Capital 7339.6 7369.1 7220.2 7386.5 7225.5
    Retained Earnings (Accumulated Deficit) 9173.6 8138.3 7222.6 6522.8 5703.9
    Unrealized Gain (Loss) -18.9 -12.7 2.8 -0.1 -4.1
    Other Equity, Total 15.9 -27.1 -15.9 0.9 101.7
    Total Liabilities & Shareholders’ Equity 21726.2 20349.2 18974.2 18150.9 16706.4
    Total Common Shares Outstanding 257.829 257.793 257.51 257.012 256.646
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 3322 2342.1 2711.65 1176.81 2087.1
    Cash From Operating Activities 4129.9 2643.5 3253.5 1569.33 1270.29
    Cash From Operating Activities 148.3 125.6 109.515 106.941 72.42
    Deferred Taxes -275.9 -154.6 277.341 167.387 -1512.32
    Non-Cash Items 594.7 435.6 209.456 184.293 385.068
    Cash Taxes Paid 1057.8 476.3 191.776 24.73 12.402
    Cash Interest Paid 52.3 56.3 54.52 55.554 66.458
    Changes in Working Capital 340.8 -105.2 -54.454 -66.101 238.02
    Cash From Investing Activities -321.1 -340.9 99.388 -1235.32 -202.158
    Capital Expenditures -204.7 -235 -259.798 -75.451 -95.524
    Other Investing Cash Flow Items, Total -116.4 -105.9 359.186 -1159.87 -106.634
    Cash From Financing Activities -67.7 -1478 -505.281 126.773 -71.219
    Financing Cash Flow Items -168.5 -130.2 -202.067 4.683 2.079
    Issuance (Retirement) of Stock, Net 186.3 -1323.4 -274.19 151.229 -60.75
    Issuance (Retirement) of Debt, Net -85.5 -24.4 -29.024 -29.139 -12.548
    Foreign Exchange Effects -29.2 -13.4 20.552 1.643 -6.182
    Net Change in Cash 3711.9 811.2 2868.16 462.428 990.727
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 699.8 3322 2503.1 1572.6 762.1
    Cash From Operating Activities 899.9 4129.9 3051.5 2096 956.2
    Cash From Operating Activities 38.8 148.3 109.9 73.2 35.9
    Deferred Taxes -113.4 -275.9 -424 -241.7 -12.3
    Non-Cash Items 135.8 594.7 430.8 341 203.3
    Cash Taxes Paid 120.3 1057.8 840.1 478.3 85
    Cash Interest Paid 11.1 52.3 41.1 27.1 13.7
    Changes in Working Capital 138.9 340.8 431.7 350.9 -32.8
    Cash From Investing Activities -1833.6 -321.1 -496.7 -112.5 -51
    Capital Expenditures -42.1 -204.7 -171.1 -116.9 -63.6
    Other Investing Cash Flow Items, Total -1791.5 -116.4 -325.6 4.4 12.6
    Cash From Financing Activities -294.7 -67.7 -107.9 -47.7 -95.4
    Financing Cash Flow Items -165.5 -168.5 -167.5 -120.2 -116.2
    Issuance (Retirement) of Stock, Net -118.6 186.3 134.7 98.1 33.7
    Issuance (Retirement) of Debt, Net -10.6 -85.5 -75.1 -25.6 -12.9
    Foreign Exchange Effects 12 -29.2 -70 -31.8 -5.9
    Net Change in Cash -1216.4 3711.9 2376.9 1904 803.9

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Vertex Company profile

    Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that develops and commercialises innovative medicines. 

    Founded in 1989, Vertex is headquartered in Boston, Massachusetts, with international headquarters in London, UK. The company focuses on health conditions like cystic fibrosis, pain, sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, duchenne muscular dystrophy and type 1 diabetes.

    The company designed and developed Symdeko/Symkevi, Orkambi and Kalydeco for cystic fibrosis, and Trikafta for patients aged six years or older with at least one F508del mutation. There are several products in the pipeline, such as VX-864 for the treatment of AAT deficiency, VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, VX- 880 for Type 1 Diabetes and VX-548, a NaV1.8 inhibitor for treatments of neuropathic and musculoskeletal pain.

    Vertex sells its products to specialty pharmacies and distributors, hospitals and clinics. It has collaborations and partnership deals with CRISPR Therapeutics AG, Moderna, Arbor Biotechnologies and several other pharma companies that support the commercialisation of drugs.

    The company went public in 1991. Vertex Pharmaceuticals Incorporated stock trades on the Nasdaq under the ticker symbol VRTX. 

    You can follow the VRTX share value and price movement live through stock charts at Capital.com.

    Industry: Bio Therapeutic Drugs

    50 Northern Avenue
    BOSTON
    MASSACHUSETTS 02210
    US

    Income Statement

    • Annual
    • Quarterly

    News

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    Higher CPI leaves traders unfazed as US equities continue to build momentum

    The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

    12:42, 15 March 2024

    People also watch

    BTC/USD

    63,522.65 Price
    +0.400% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    XRP/USD

    0.50 Price
    +0.990% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    ETH/USD

    3,094.17 Price
    +0.280% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    Gold

    2,370.62 Price
    -0.580% 1D Chg, %
    Long position overnight fee -0.0188%
    Short position overnight fee 0.0106%
    Overnight fee time 21:00 (UTC)
    Spread 0.50

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading